Lexicon Presents Class Of Compounds Modulating TPH1, The Target For Its LX1031 Investigational Drug For Irritable Bowel Syndrome
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by the company as potential treatments for irritable bowel syndrome (IBS) and other gastrointestinal disorders. LX1031 is currently under evaluation in a Phase 1b clinical trial in healthy volunteers.
